However, poor tumor cell targeting and insufficient drug delivery imposed by the blood-brain barrier (BBB) are major obstacles to effective treatment of HER2-positive breast cancer brain metastases (BCBM) [91,92]. Here, ERBB2 is linked to breast carcinoma.